Back to top
more

Prothena (PRTA)

(Delayed Data from NSDQ)

$17.70 USD

17.70
265,138

+0.21 (1.20%)

Updated Nov 8, 2024 04:00 PM ET

After-Market: $17.68 -0.02 (-0.11%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value D Growth D Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (87 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Prothena (PRTA) Upgraded to Buy: What Does It Mean for the Stock?

by Zacks Equity Research

Prothena (PRTA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Strength Seen in Prothena (PRTA): Can Its 15.0% Jump Turn into More Strength?

by Zacks Equity Research

Prothena (PRTA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Eli Lilly Secures Approval for Alzheimer's Drug Kisunla in Japan

by Zacks Equity Research

Japan is the second major market where LLY's Kisunla has been approved. The drug was first approved in the United States in July 2024.

What Makes Prothena (PRTA) a New Buy Stock

by Zacks Equity Research

Prothena (PRTA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Prothena (PRTA) Q2 Earnings Benefit From Collaboration Revenues

by Zacks Equity Research

Prothena (PRTA) records impressive second-quarter earnings as the top line benefits from a $80-million payment from collaboration partner BMY.

Prothena (PRTA) Q2 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Prothena (PRTA) delivered earnings and revenue surprises of 220.79% and 487.72%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Merus N.V. (MRUS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

by Zacks Equity Research

Merus (MRUS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Prothena (PRTA) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

by Zacks Equity Research

Prothena (PRTA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Legend Biotech (LEGN) Surges 12.1%: Is This an Indication of Further Gains?

by Zacks Equity Research

Legend Biotech (LEGN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Eli Lilly (LLY) Gets FDA Nod for Alzheimer's Drug Donanemab

by Zacks Equity Research

Eli Lilly's (LLY) Alzheimer's disease drug, Kisunla (donanemab), wins FDA approval. Kisunla will be the second drug on the market to treat the disease.

Prothena (PRTA) Moves 9.3% Higher: Will This Strength Last?

by Zacks Equity Research

Prothena (PRTA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

Sanghamitra Saha headshot

Can Eli Lilly ETFs Surge on Approval of Alzheimer's Drug?

by Sanghamitra Saha

On Jun 10, the FDA's Peripheral and Central Nervous System Drugs Advisory Committee (PCNS) voted 11-0, unanimously recommending the approval of Eli Lilly's (LLY) Alzheimer's disease drug, donanemab.

Alzheimer's in Focus as FDA Panel Endorses Lilly's Donanemab (Revised)

by Zacks Equity Research

If Eli Lilly's (LLY) donanemab is approved by the FDA, it will become the second drug approved by the FDA to reduce the clinical decline associated with Alzheimer's disease.

The Zacks Analyst Blog Highlights Biogen, Eli Lilly's, Prothena and AC Immune (Revised)

by Zacks Equity Research

Biogen, Eli Lilly's, Prothena and AC Immune are included in this Analyst Blog.

The Zacks Analyst Blog Highlights Biogen, Eli Lilly's, Prothena and AC Immune

by Zacks Equity Research

Biogen, Eli Lilly's, Prothena and AC Immune are included in this Analyst Blog.

Kinjel Shah headshot

Alzheimer's in Focus as FDA Panel Endorses Lilly's Donanemab

by Kinjel Shah

If Eli Lilly's (LLY) donanemab is approved by the FDA, it will become the second drug approved by the FDA to reduce the clinical decline associated with Alzheimer's disease.

Eli Lilly (LLY) Alzheimer's Drug Donanemab Gets FDA Panel Nod

by Zacks Equity Research

Eli Lilly (LLY) Alzheimer's disease drug, donanemab, receives Peripheral and Central Nervous System Drugs Advisory Committee (PCNS) recommendation.

Biogen (BIIB) & Eisai's Leqembi sBLA Gets FDA Acceptance

by Zacks Equity Research

FDA accepts Biogen's (BIIB) partner Eisai's sBLA for a maintenance intravenous dosing version of Alzheimer's drug Leqembi. The final FDA decision is expected on Jan 25, 2025.

Why Is Prothena (PRTA) Down 1.5% Since Last Earnings Report?

by Zacks Equity Research

Prothena (PRTA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Prothena (PRTA), Bristol Myers Tie Up for Second Neuro Candidate

by Zacks Equity Research

Prothena (PRTA) announces that Bristol Myers is exercising its option for the second time, thereby in-licensing exclusive global rights for PRX019 to potentially treat neurodegenerative diseases.

Prothena (PRTA) Q1 Earnings Miss Estimates on Higher R&D Expenses

by Zacks Equity Research

Prothena (PRTA) posts a wider-than-expected loss in the first quarter on lower revenues and higher costs.

Prothena (PRTA) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

Prothena (PRTA) delivered earnings and revenue surprises of -10.74% and 98.67%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Adaptive Biotechnologies (ADPT) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Adaptive Biotechnologies (ADPT) delivered earnings and revenue surprises of 5.71% and 0.78%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: Prothena (PRTA) Q1 Earnings Expected to Decline

by Zacks Equity Research

Prothena (PRTA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

J&J (JNJ) to Begin Pharma Q1 Earnings Season: What's in Store?

by Zacks Equity Research

J&J's (JNJ) Innovative Medicines unit sales are expected to have been driven by drugs like Darzalex and Stelara. Surgical procedure recovery and new products are likely to have driven MedTech sales.